Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Depreciation and Depletion (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Depreciation and Depletion for 12 consecutive years, with $4.7 million as the latest value for Q4 2025.

  • Quarterly Depreciation and Depletion fell 6.0% to $4.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.5 million through Dec 2025, up 1.04% year-over-year, with the annual reading at $19.5 million for FY2025, 0.0% changed from the prior year.
  • Depreciation and Depletion for Q4 2025 was $4.7 million at Myriad Genetics, down from $4.8 million in the prior quarter.
  • The five-year high for Depreciation and Depletion was $8.7 million in Q1 2023, with the low at $2.6 million in Q3 2021.
  • Average Depreciation and Depletion over 5 years is $4.1 million, with a median of $3.8 million recorded in 2021.
  • The sharpest move saw Depreciation and Depletion surged 210.71% in 2023, then crashed 43.68% in 2024.
  • Over 5 years, Depreciation and Depletion stood at $3.2 million in 2021, then dropped by 3.12% to $3.1 million in 2022, then skyrocketed by 38.71% to $4.3 million in 2023, then grew by 16.28% to $5.0 million in 2024, then fell by 6.0% to $4.7 million in 2025.
  • According to Business Quant data, Depreciation and Depletion over the past three periods came in at $4.7 million, $4.8 million, and $4.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.